Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions

Molecular and Cellular Biology

Volumn 26, Issue 24, 2006, Pages 9377-9386

  Bartz, Steven R ^a   Zhang, Zhan ^a   Burchard, Julja ^a   Imakura, Maki ^a   Martin, Melissa ^a   Palmieri, Anthony ^a   Needham, Rachel ^a   Guo, Jie ^a   Gordon, Marcia ^a   Chung, Namjin ^b   Warrener, Paul ^a   Jackson, Aimee L ^a   Carleton, Michael ^a   Oatley, Melissa ^b   Locco, Louis ^b   Santini, Francesca ^b   Smith, Todd ^b   Kunapuli, Priya ^b   Ferrer, Marc ^b   Strulovici, Berta ^b   Friend, Stephen H ^b   Linsley, Peter S ^a   more..

^a ROSETTA INPHARMATICS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; GEMCITABINE; PACLITAXEL; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; BRCA2 GENE; CANCER CELL; CELL LINE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; FUNCTIONAL GENOMICS; GENE DISRUPTION; GENE FUNCTION; GENE IDENTIFICATION; GENE LIBRARY; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENOME ANALYSIS; HELA CELL; HUMAN; HUMAN CELL; KNOCKOUT GENE; MOLECULAR MECHANICS; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR CELL; WILD TYPE;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; NEOPLASMS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845464255     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01229-06     Document Type: Article

References (64)

1. Abraham, R. T. 2001. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2177-2196.
2. Anand, S., S. Penrhyn-Lowe, and A. R. Venkitaraman. 2003. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51-62.
3. Ashrafi, K., F. Y. Chang, J. L. Watts, A. G. Fraser, R. S. Kamath, J. Ahringer, and G. Ruvkun. 2003. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421:268-272.
4. Aza-Blanc, P., C. L. Cooper, K. Wagner, S. Batalov, Q. L. Deveraux, and M. P. Cooke. 2003. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell 12:627-637.
5. Bartek, J., and J. Lukas. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429.
6. Berns, K., E. M. Hijmans, J. Mullenders, T. R. Brummelkamp, A. Velds, M. Heimerikx, R. M. Kerkhoven, M. Madiredjo, W. Nijkamp, B. Weigelt, R. Agami, W. Ge, G. Cavet, P. S. Linsley, R. L. Beijersbergen, and R. Bernards. 2004. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428:431-437.
7. Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
8. Bryant, H. E., N. Schultz, H. D. Thomas, K. M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N. J. Curtin, and T. Helleday. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917.
9. Cantor, S. B., and P. R. Andreassen. 2006. Assessing the link between BACH1 and BRCA1 in the FA pathway. Cell Cycle 5:164-167.
10. Cass, I., R. L. Baldwin, T. Varkey, R. Moslehi, S. A. Narod, and B. Y. Karlan. 2003. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195.
11. D'Andrea, A. D., and M. Grompe. 2003. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 3:23-34.
12. Dong, Y., M. A. Hakimi, X. Chen, E. Kumaraswamy, N. S. Cooch, A. K. Godwin, and R. Shiekhattar. 2003. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell 12:1087-1099.
13. Doye, V., and E. C. Hurt. 1995. Genetic approaches to nuclear pore structure and function. Trends Genet. 11:235-241.
14. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
15. El-Deiry, W. S. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495.
16. Farmer, H., N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson, T. B. Richardson, M. Santarosa, K. J. Dillon, I. Hickson, C. Knights, N. M. Martin, S. P. Jackson, G. C. Smith, and A. Ashworth. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921.
17. Fedier, A., R. A. Steiner, V. A. Schwarz, L. Lenherr, U. Haller, and D. Fink. 2003. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22:1169-1173.
18. Fire, A., S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
19. Fridman, J. S., and S. W. Lowe. 2003. Control of apoptosis by p53. Oncogene 22:9030-9040.
20. Friend, S. H. 2005. Emerging approaches in molecular profiling impacting oncology drug discovery. Cold Spring Harb. Symp. Quant. Biol. 70:445-448.
21. Friend, S. H., and A. Oliff. 1998. Emerging uses for genomic information in drug discovery. N. Engl. J. Med. 338:125-126.
22. Game, J. C., M. S. Williamson, T. Spicakova, and M. Brown. 2006. The RAD6/BRE1 histone modification pathway in Saccharomyces confers radiation resistance through a RAD51-dependent process that is independent of RAD18. Genetics 173:1951-1968.
23. Gavin, A. C., P. Aloy, P. Grandi, R. Krause, M. Boesche, M. Marzioch, C. Rau, L. J. Jensen, S. Bastuck, B. Dumpelfeld, A. Edelmann, M. A. Heurtier, V. Hoffman, C. Hoefert, K. Klein, M. Hudak, A. M. Michon, M. Schelder, M. Schirle, M. Remor, T. Rudi, S. Hooper, A. Bauer, T. Bouwmeester, G. Casari, G. Drewes, G. Neubauer, J. M. Rick, B. Kuster, P. Bork, R. B. Russell, and G. Superti-Furga. 2006. Proteome survey reveals modularity of the yeast cell machinery. Nature 440:631-636.
24. Gavin, A. C., M. Bosche, R. Krause, P. Grandi, M. Marzioch, A. Bauer, J. Schultz, J. M. Rick, A. M. Michon, C. M. Cruciat, M. Remor, C. Hofert, M. Schelder, M. Brajenovic, H. Ruffner, A. Merino, K. Klein, M. Hudak, D. Dickson, T. Rudi, V. Gnau, A. Bauch, S. Bastuck, B. Huhse, C. Leutwein, M. A. Heurtier, R. R. Copley, A. Edelmann, E. Querfurth, V. Rybin, G. Drewes, M. Raida, T. Bouwmeester, P. Bork, B. Seraphin, B. Kuster, G. Neubauer, and G. Superti-Furga. 2002. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415:141-147.
25. Greenberg, R. A., B. Sobhian, S. Pathania, S. B. Cantor, Y. Nakatani, and D. M. Livingston. 2006. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev. 20:34-46.
26. Gu, W., L. Putral, K. Hengst, K. Minto, N. A. Saunders, G. Leggatt, and N. A. McMillan. 30 June 2006. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther. [Epub ahead of print.]
27. Gudmundsdottir, K., C. J. Lord, E. Witt, A. N. Tutt, and A. Ashworth. 2004. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep. 5:989-993.
28. Hartwell, L. H., P. Szankasi, C. J. Roberts, A. W. Murray, and S. H. Friend. 1997. Integrating genetic approaches into the discovery of anticancer drugs. Science 278:1064-1068.
29. Hata, T., T. Furukawa, M. Sunamura, S. Egawa, F. Motoi, N. Ohmura, T. Marumoto, H. Saya, and A. Horii. 2005. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 65:2899-2905.
30. Hopkins, A. L., and C. R. Groom. 2002. The druggable genome. Nat. Rev. Drug Discov. 1:727-730.
31. Hewlett, N. G., T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz, C. De Die-Smulders, N. Persky, M. Grompe, H. Joenje, G. Pals, H. Ikeda, E. A. Fox, and A. D. D'Andrea. 2002. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609.
32. Hwang, W. W., S. Venkatasubrahmanyam, A. G. Ianculescu, A. Tong, C. Boone, and H. D. Madhani. 2003. A conserved RING finger protein required for histone H2B monoubiquitination and cell size control. Mol. Cell 11:261-266.
33. Jackson, A. L., S. R. Bartz, J. Schelter, S. V. Kobayashi, J. Burchard, M. Mao, B. Li, G. Cavet, and P. S. Linsley. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21:635-637.
34. Jackson, A. L., J. Burchard, D. Leake, A. Reynolds, J. Schelter, J. Guo, J. M. Johnson, L. Lim, J. Karpilow, K. Nichols, W. Marshall, A. Khvorova, and P. S. Linsley. 2006. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12:1197-1205.
35. Jackson, A. L., J. Burchard, J. Schelter, B. N. Chau, M. Cleary, L. Lim, and P. S. Linsley. 2006. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12:1179-1187.
36. Jen, K. Y., and V. G. Cheung. 2005. Identification of novel p53 target genes in ionizing radiation response. Cancer Res. 65:7666-7673.
37. Kaelin, W. G., Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5:689-698.
38. Kamath, R. S., A. G. Fraser, Y. Dong, G. Poulin, R. Durbin, M. Gotta, A. Kanapin, N. Le Bot, S. Moreno, M. Sohrmann, D. P. Welchman, P. Zipperlen, and J. Ahringer. 2003. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421:231-237.
39. Kennedy, R. D., J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin. 2004. The role of BRCA1 in the cellular response to chemotherapy. J. Natl. Cancer Inst. 96:1659-1668.
40. Kolfschoten, I. G., B. van Leeuvren, K. Berns, J. Mullenders, R. L. Beijersbergen, R. Bernards, P. M. Voorhoeve, and R. Agami. 2005. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121:849-858.
41. Koniaras, K., A. R. Cuddihy, H. Christopoulos, A. Hogg, and M. J. O'Connell. 2001. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20:7453-7463.
42. Lum, L., S. Yao, B. Mozer, A. Rovescalli, D. Von Kessler, M. Nirenberg, and P. A. Beachy. 2003. Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. Science 299:2039-2045.
43. Lum, P. Y., C. D. Armour, S. B. Stepaniants, G. Cavet, M. K. Wolf, J. S. Butler, J. C. Hinshaw, P. Garnier, G. D. Prestwich, A. Leonardson, P. Garrett-Engele, C. M. Rush, M. Bard, G. Schimmack, J. W. Phillips, C. J. Roberts, and D. D. Shoemaker. 2004. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116:121-137.
44. MacKeigan, J. P., L. O. Murphy, and J. Blenis. 2005. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7:591-600.
45. Majdak, E. J., J. Debniak, T. Milczek, C. J. Cornelisse, P. Devilee, J. Emerich, J. Jassem, and G. H. De Bock. 2005. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104:1004-1012.
46. Mantovani, F., and L. Banks. 2001. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20:7874-7887.
47. Nakanishi, K., Y. G. Yang, A. J. Pierce, T. Taniguchi, M. Digweed, A. D. D'Andrea, Z. Q. Wang, and M. Jasin. 2005. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl. Acad. Sci. USA 102:1110-1115.
48. Narod, S. A., and W. D. Foulkes. 2004. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4:665-676.
49. Paddison, P. J., J. M. Silva, D. S. Conklin, M. Schlabach, M. Li, S. Aruleba, V. Balija, A. O'Shaughnessy, L. Gnoj, K. Scobie, K. Chang, T. Westbrook, M. Cleary, R. Sachidanandam, W. R. McCombie, S. J. Elledge, and G. J. Hannon. 2004. A resource for large-scale RNA-interference-based screens in mammals. Nature 428:427-431.
50. Parsons, A. B., R. L. Brost, H. Ding, Z. Li, C. Zhang, B. Sheikh, G. W. Brown, P. M. Kane, T. R. Hughes, and C. Boone. 2004. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22:62-69.
51. Prakash, S., R. E. Johnson, and L. Prakash. 2005. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu. Rev. Biochem. 74:317-353.
52. Rottmann, S., Y. Wang, M. Nasoff, Q. L. Deveraux, and K. C. Quon. 2005. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc. Natl. Acad. Sci. USA 102:15195-15200.
53. Sampath, D., V. A. Rao, and W. Plunkett. 2003. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22:9063-9074.
54. Simon, J. A., P. Szankasi, D. K. Nguyen, C. Ludlow, H. M. Dunstan, C. J. Roberts, E. L. Jensen, L. M. Hartwell, and S. H. Friend. 2000. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 60:328-333.
55. Turner, N., A. Tutt, and A. Ashworth. 2004. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4:814-819.
56. van Haaften, G., N. L. Vastenhouw, E. A. Nollen, R. H. Plasterk, and M. Tijsterman. 2004. Gene interactions in the DNA damage-response pathway identified by genome-wide RNA-interference analysis of synthetic lethality. Proc. Natl. Acad. Sci. USA 101:12992-12996.
57. Vousden, K. H., and X. Lu. 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604.
58. Wang, Q., S. Fan, A. Eastman, P. J. Worland, E. A. Sausville, and P. M. O'Connor. 1996. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88:956-965.
59. Westbrook, T. F., E. S. Martin, M. R. Schlabach, Y. Leng, A. C. Liang, B. Feng, J. J. Zhao, T. M. Roberts, G. Mandel, G. J. Hannon, R. A. Depinho, L. Chin, and S. J. Elledge. 2005. A genetic screen for candidate tumor suppressors identifies REST. Cell 121:837-848.
60. Wood, A., N. J. Krogan, J. Dover, J. Schneider, J. Heidt, M. A. Boateng, K. Dean, A. Golshani, Y. Zhang, J. F. Greenblatt, M. Johnston, and A. Shilatifard. 2003. Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Mol. Cell 11:267-274.
61. Wu, H. I., J. A. Brown, M. J. Dorie, L. Lazzeroni, and J. M. Brown. 2004. Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. Cancer Res. 64:3940-3948.
62. Yarden, R. I., S. Pardo-Reoyo, M. Sgagias, K. H. Cowan, and L. C. Brody. 2002. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 30:285-289.
63. Yee, C., I. Krishnan-Hewlett, C. C. Baker, R. Schlegel, and P. M. Howley. 1985. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119:361-366.
64. Yun, J., Q. Zhong, J. Y. Kwak, and W. H. Lee. 2005. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene 24:4009-4016.